Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 109

1.

Anticoagulant therapy in patients with liver cirrhosis and portal vein thrombosis: insights for the clinician.

Basili S, Pastori D, Raparelli V, Violi F.

Therap Adv Gastroenterol. 2018 Sep 6;11:1756284818793561. doi: 10.1177/1756284818793561. eCollection 2018. Review.

2.

Correction to: Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study.

Raparelli V, Pastori D, Pignataro SF, Vestri AR, Pignatelli P, Cangemi R, Proietti M, Davì G, Hiatt WR, Lip GYH, Corazza GR, Perticone F, Violi F, Basili S; ARAPACIS Study Collaborators.

Intern Emerg Med. 2018 Aug 3. doi: 10.1007/s11739-018-1922-y. [Epub ahead of print]

PMID:
30076553
3.

Antioxidant activity from extra virgin olive oil via inhibition of hydrogen peroxide-mediated NADPH-oxidase 2 activation.

Carnevale R, Nocella C, Cammisotto V, Bartimoccia S, Monticolo R, D'Amico A, Stefanini L, Pagano F, Pastori D, Cangemi R, Violi F.

Nutrition. 2018 Mar 29;55-56:36-40. doi: 10.1016/j.nut.2018.03.045. [Epub ahead of print]

PMID:
29960154
4.

Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: Biomarker substudy results from a prospective study with rivaroxaban (X-TRA).

Miyazawa K, Pastori D, Hammerstingl C, Cappato R, Meng IL, Kramer F, Cohen A, Schulz A, Eickels MV, Lip GYH, Marin F; X-TRA study investigators.

Ann Med. 2018 Jun 29:1-27. doi: 10.1080/07853890.2018.1495337. [Epub ahead of print]

PMID:
29956554
5.

Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists-naive patients with atrial fibrillation.

Pastori D, Pignatelli P, Cribari F, Carnevale R, Saliola M, Violi F, Lip GY.

Am Heart J. 2018 Jun;200:32-36. doi: 10.1016/j.ahj.2018.03.004. Epub 2018 Mar 10.

PMID:
29898846
6.

Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants.

Pastori D, Lip GYH, Farcomeni A, Del Sole F, Sciacqua A, Perticone F, Marcucci R, Grifoni E, Pignatelli P, Violi F; ATHERO-AF study group.

Int J Cardiol. 2018 Aug 1;264:58-63. doi: 10.1016/j.ijcard.2018.01.097.

PMID:
29776574
7.

Gut-derived lipopolysaccharides increase post-prandial oxidative stress via Nox2 activation in patients with impaired fasting glucose tolerance: effect of extra-virgin olive oil.

Carnevale R, Pastori D, Nocella C, Cammisotto V, Bartimoccia S, Novo M, Del Ben M, Farcomeni A, Angelico F, Violi F.

Eur J Nutr. 2018 May 16. doi: 10.1007/s00394-018-1718-x. [Epub ahead of print]

PMID:
29766292
8.

Blood hydrogen peroxide break-down activity in healthy subjects and in patients at risk of cardiovascular events.

Carnevale R, Nocella C, Pignatelli P, Bartimoccia S, Stefanini L, Basili S, Novo M, D'Amico A, Cammisotto V, Pastori D, Violi F.

Atherosclerosis. 2018 Jul;274:29-34. doi: 10.1016/j.atherosclerosis.2018.04.025. Epub 2018 Apr 25.

PMID:
29747088
9.

Prognostic and therapeutic implications of vascular disease in patients with atrial fibrillation.

Shahid F, Pastori D, Violi F, Lip GYH.

Pharmacol Res. 2018 Jun;132:149-159. doi: 10.1016/j.phrs.2018.04.019. Epub 2018 Apr 23. Review.

PMID:
29698794
10.

Response to Duret et al.

Pastori D, Baratta F, Ernesti I, Violi F, Angelico F, Del Ben M.

Am J Gastroenterol. 2018 May;113(5):775-776. doi: 10.1038/s41395-018-0055-2. Epub 2018 Apr 23. No abstract available.

PMID:
29681626
11.

Inflammation and the risk of atrial high-rate episodes (AHREs) in patients with cardiac implantable electronic devices.

Pastori D, Miyazawa K, Li Y, Shahid F, Hado H, Lip GYH.

Clin Res Cardiol. 2018 Sep;107(9):772-777. doi: 10.1007/s00392-018-1244-0. Epub 2018 Apr 17.

12.

Risk factors for new-onset atrial fibrillation: A focus on Asian populations.

Li Y, Pastori D, Guo Y, Wang Y, Lip GYH.

Int J Cardiol. 2018 Jun 15;261:92-98. doi: 10.1016/j.ijcard.2018.02.051.

PMID:
29657061
13.

Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation.

Pastori D, Farcomeni A, Saliola M, Del Sole F, Pignatelli P, Violi F, Lip GYH; ATHERO-AF Study Group.

Eur J Intern Med. 2018 Aug;54:34-39. doi: 10.1016/j.ejim.2018.04.007. Epub 2018 Apr 11.

PMID:
29655807
14.

Changes in renal function in patients with atrial fibrillation: Efficacy and safety of the non-vitamin K antagonist oral anticoagulants.

Miyazawa K, Pastori D, Lip GYH.

Am Heart J. 2018 Apr;198:166-168. doi: 10.1016/j.ahj.2017.11.015. Epub 2018 Jan 4. No abstract available.

PMID:
29653639
15.

Fitting the right non-vitamin K antagonist oral anticoagulant to the right patient with non-valvular atrial fibrillation: an evidence-based choice.

Li YG, Pastori D, Lip GYH.

Ann Med. 2018 Jun;50(4):288-302. doi: 10.1080/07853890.2018.1460489. Epub 2018 Apr 15. Erratum in: Ann Med. 2018 Jun;50(4):361.

PMID:
29608110
16.

Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study.

Raparelli V, Pastori D, Pignataro SF, Vestri AR, Pignatelli P, Cangemi R, Proietti M, Davì G, Hiatt WR, Lip GYH, Corazza GR, Perticone F, Violi F, Basili S; ARAPACIS Study Collaborators.

Intern Emerg Med. 2018 Aug;13(5):651-660. doi: 10.1007/s11739-018-1835-9. Epub 2018 Mar 26. Erratum in: Intern Emerg Med. 2018 Aug 3;:.

PMID:
29582316
17.

Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients.

Pastori D, Rivera-Caravaca JM, Esteve-Pastor MA, Roldán V, Marín F, Pignatelli P, Violi F, Lip GYH.

Circ J. 2018 Apr 25;82(5):1286-1292. doi: 10.1253/circj.CJ-17-1318. Epub 2018 Mar 16.

18.

Oxidative stress and cardiovascular disease: new insights.

Pignatelli P, Menichelli D, Pastori D, Violi F.

Kardiol Pol. 2018;76(4):713-722. doi: 10.5603/KP.a2018.0071. Epub 2018 Mar 14.

19.

Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants.

Pastori D, Lip GYH, Farcomeni A, Del Sole F, Sciacqua A, Perticone F, Marcucci R, Grifoni E, Pignatelli P, Violi F; ATHERO-AF study group.

Data Brief. 2018 Feb 6;17:830-836. doi: 10.1016/j.dib.2018.01.109. eCollection 2018 Apr.

20.

Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy.

Di Costanzo A, Belardinilli F, Bailetti D, Sponziello M, D'Erasmo L, Polimeni L, Baratta F, Pastori D, Ceci F, Montali A, Girelli G, De Masi B, Angeloni A, Giannini G, Del Ben M, Angelico F, Arca M.

Sci Rep. 2018 Feb 27;8(1):3702. doi: 10.1038/s41598-018-21939-0.

Supplemental Content

Loading ...
Support Center